Edition:
United Kingdom

Rocky Swift

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

27 Dec 2019

TOKYO Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.

Astellas Pharma buys Xyphos Biosciences, deal worth up to $665 mln

27 Dec 2019

Dec 27 Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition in as many months.

Muddy Waters rebukes Japan, French efforts to rein in short sales

05 Dec 2019

A move by Japan's $1.47 trillion (1.15 trillion pounds) Government Pension Investment Fund (GPIF) to suspend share lending for short sales adds to a global trend that subverts corporate governance, said prominent short seller Muddy Waters Capital LLC.

Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib

25 Nov 2019

(This Nov. 23rd story corrects fiscal year of expected regulatory approval in the 10th paragraph to March-end 2021, not March-end 2020)

Biotech-for-hire PeptiDream charts new path and becomes short target

14 Nov 2019

TOKYO The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target

13 Nov 2019

TOKYO, Nov 13 The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

RPT-Stung by WeWork, SoftBank boss Son charts more cautious IPO course

07 Nov 2019

TOKYO, Nov 7 Fresh from the WeWork debacle, SoftBank CEO Masayoshi Son says he now aims to be more cautious about the timings of IPOs, a shift that could squeeze the Japanese company's funding and increase its reliance on its lower-growth telecom business.

Stung by WeWork, SoftBank boss Son charts more cautious IPO course

07 Nov 2019

TOKYO Fresh from the WeWork debacle, SoftBank CEO Masayoshi Son says he now aims to be more cautious about the timings of IPOs, a shift that could squeeze the Japanese company's funding and increase its reliance on its lower-growth telecom business.

Stung by WeWork, SoftBank boss Son charts more cautious IPO course

07 Nov 2019

TOKYO, Nov 7 Fresh from the WeWork debacle, SoftBank CEO Masayoshi Son says he now aims to be more cautious about the timings of IPOs, a shift that could squeeze the Japanese company's funding and increase its reliance on its lower-growth telecom business.

World News